{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:31:55Z","timestamp":1786710715756,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032418","name":"Fondazione GIMEMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jval.2026.06.002","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:50:31Z","timestamp":1782229831000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stakeholder Perspectives on Potential Open-Label Bias in Patient-Reported Outcome Results From Cancer Clinical Trials: Evidence From the IMPROvE Project"],"prefix":"10.1016","author":[{"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Krepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil K.","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Anota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2026.06.002_bib1","series-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims","year":"2009"},{"issue":"11","key":"10.1016\/j.jval.2026.06.002_bib2","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1038\/s41591-025-03906-1","article-title":"Patient-reported outcome measures add value as clinical trial endpoints","volume":"31","author":"Crossnohere","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jval.2026.06.002_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/clpt.2011.207","article-title":"Blinding in randomized clinical trials: imposed impartiality","volume":"90","author":"Hr\u00f3bjartsson","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jval.2026.06.002_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.jval.2026.06.002_bib7","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1002\/cam4.3335","article-title":"Investigating the impact of open label design on patient-reported outcome results in prostate cancer randomized controlled trials","volume":"9","author":"Mouillet","year":"2020","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.jval.2026.06.002_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jnci\/djab177","article-title":"Impact of blinding on patient-reported outcome differences between treatment arms in cancer randomized controlled trials","volume":"114","author":"Efficace","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jval.2026.06.002_bib9","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study","volume":"368","author":"Moustgaard","year":"2020","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jval.2026.06.002_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad002","article-title":"Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials","volume":"7","author":"Lord-Bessen","year":"2023","journal-title":"JNCI Cancer Spectr"},{"issue":"3","key":"10.1016\/j.jval.2026.06.002_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s11136-021-02945-8","article-title":"Impact of open-label versus blinded study design on patient-reported outcomes data in randomized clinical trials of immunotherapy in advanced or metastatic cancer patients: a systematic review","volume":"31","author":"Anota","year":"2022","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jval.2026.06.002_bib12","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ije\/dyu115","article-title":"Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies","volume":"43","author":"Hr\u00f3bjartsson","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"6","key":"10.1016\/j.jval.2026.06.002_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7326\/0003-4819-157-6-201209180-00537","article-title":"Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials","volume":"157","author":"Savovi\u0107","year":"2012","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jval.2026.06.002_bib14","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jval.2023.01.017","article-title":"A review of labeling based on patient-reported outcome endpoints for new oncology drugs approved by the European Medicines Agency (2017-2021)","volume":"26","author":"Gnanasakthy","year":"2023","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.06.002_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.14425","article-title":"Patient-reported outcomes in Phase 3 clinical trials for blood cancers: a systematic review","volume":"7","author":"Patel","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.jval.2026.06.002_bib16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jval.2020.12.015","article-title":"Does knowledge of treatment assignment affect patient report of symptoms, function, and health status? An evaluation using multiple myeloma trials","volume":"24","author":"Roydhouse","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2026.06.002_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"10.1016\/j.jval.2026.06.002_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115077","article-title":"Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: a systematic review and meta-analysis","volume":"213","author":"D\u2019Ambrosio","year":"2024","journal-title":"Eur J Cancer"},{"issue":"32","key":"10.1016\/j.jval.2026.06.002_bib19","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-free survival should not be used as a primary end point for registration of anticancer drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jval.2026.06.002_bib20","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1093\/annonc\/mdw266","article-title":"Is it best to expect the worst? Influence of patients\u2019 side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study","volume":"27","author":"Nestoriuc","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.jval.2026.06.002_bib21","doi-asserted-by":"crossref","DOI":"10.2196\/25230","article-title":"Social media and the transformation of the physician\u2014patient relationship: viewpoint","volume":"23","author":"Forgie","year":"2021","journal-title":"J Med Internet Res"},{"issue":"10","key":"10.1016\/j.jval.2026.06.002_bib22","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2023.2944","article-title":"Miscommunication in cancer care-do you hear what I hear?","volume":"9","author":"Sullivan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.jval.2026.06.002_bib23","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1002\/cncr.29530","article-title":"Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.jval.2026.06.002_bib24","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa1204410","article-title":"Patients\u2019 expectations about effects of chemotherapy for advanced cancer","volume":"367","author":"Weeks","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jval.2026.06.002_bib25","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(23)00157-2","article-title":"Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures","volume":"24","author":"Pe","year":"2023","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jval.2026.06.002_bib26","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jval.2026.06.002_bib27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T11:37:30Z","timestamp":1786707450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"alternative-id":["S1098301526025167"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stakeholder Perspectives on Potential Open-Label Bias in Patient-Reported Outcome Results From Cancer Clinical Trials: Evidence From the IMPROvE Project","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}